Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1-3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1-4), platelet derived growth factor receptor α (PDGFRα), KIT, and RET. We examined the antitumor activity of lenvatinib against human thyroid cancer xenograft models in nude mice. Orally administered lenvatinib showed significant antitumor activity in 5 differentiated thyroid cancer (DTC), 5 anaplastic thyroid cancer (ATC), and 1 medullary thyroid cancer (MTC) xenograft models. Lenvatinib also showed antiangiogenesis activity against 5 DTC and 5 ATC xenografts, while lenvatinib showed in vitro antiproliferative activity against only 2 of 11 thyroid cancer cell lines: that is, RO82-W-1 and TT cells. Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2. Lenvatinib also inhibited the phosphorylation of RET with the activated mutation C634W in TT cells. These data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Lenvatinib is an oral TKI of VEGFRs, FGFRs, PDGFRα, KIT, and RET.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Sherma, S. I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12488-9 · Cited by 925
BindingDB (2025) · PubMed · doi:10.7270/q2pc374f · Cited by 924
Carlson, K. M., Dou, S., Chi, D., Scavarda, N., Toshima, K., Jackson, C. E., Wells, S. A., Goodfellow, P. J., & Donis-Keller, H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1579 · Cited by 600
Robbins, R. J., Wan, Q., Grewal, R. K., Reibke, R., Gonen, M., Strauss, H. W., Tuttle, R. M., Drucker, W., & Larson, S. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1534 · Cited by 587
Roman, S., Lin, R., & Sosa, J. A. (2006) · Cancer · doi:10.1002/cncr.22244 · Cited by 548
Elisei, R., Cosci, B., Romei, C., Bottici, V., Renzini, G., Molinaro, E., Agate, L., Vivaldi, A., Faviana, P., Basolo, F., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1714 · Cited by 531
Yamamoto, Y., Matsui, J., Matsushima, T., Obaishi, H., Miyazaki, K., Nakamura, K., Tohyama, O., Semba, T., Yamaguchi, A., Hoshi, S., et al. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-18 · Cited by 507
Self-citationCrystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
Mohammadi, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.20.5896 · Cited by 482
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies
Smallridge, R. C., Marlow, L. A., & Copland, J. A. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-08-0154 · Cited by 390
Point Mutations of Ras Oncogenes are an Early Event in Thyroid Tumorigenesis
Namba, H., Rubin, S. A., & Fagin, J. A. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-10-1474 · Cited by 356
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pacini, F., Castagna, M. G., Brilli, L., & Pentheroudakis, G. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq190 · Cited by 350
Bounacer, A., Wicker, R., Caillou, B., Cailleux, A. F., Sarasin, A., Schlumberger, M., & Suárez, H. G. (1997) · Oncogene · doi:10.1038/sj.onc.1200206 · Cited by 339
Molecular genetics of multiple endocrine neoplasia types 1 and 2
Marx, S. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1610 · Cited by 322
Specific Pattern of RAS Oncogene Mutations in Follicular Thyroid Tumors
Vasko, V., Ferrand, M., Di Cristofaro, J., Carayon, P., Henry, J. F., & de Micco, C. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021186 · Cited by 310
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Pacini, F., Castagna, M. G., Brilli, L., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds230 · Cited by 290
Okamoto, K., Kodama, K., Takase, K., Sugi, N. H., Yamamoto, Y., Iwata, M., & Tsuruoka, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.007 · Cited by 288
Self-citationSomatic mutations in the RET proto‐oncogene in sporadic medullary thyroid carcinoma
Marsh, D. J., Learoyd, D. L., Andrew, S. D., Krishnan, L., Pojer, R., Richardson, A., Delbridge, L., Eng, C., & Robinson, B. G. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.681503.x · Cited by 279
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Pasieka, J. L. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200301000-00012 · Cited by 191
Boss, D. S., Glen, H., Beijnen, J. H., Keesen, M., Morrison, R., Tait, B., Copalu, W., Mazur, A., Wanders, J., O'Brien, J. P., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.154 · Cited by 183
New therapeutic approaches to treat medullary thyroid carcinoma
Schlumberger, M., Carlomagno, F., Baudin, E., Bidart, J. M., & Santoro, M. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0717 · Cited by 172
Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
Yamada, K., Yamamoto, N., Yamada, Y., Nokihara, H., Fujiwara, Y., Hirata, T., Koizumi, F., Nishio, K., Koyama, N., & Tamura, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2638 · Cited by 162
Multikinase inhibitors: a new option for the treatment of thyroid cancer
Gild, M. L., Bullock, M., Robinson, B. G., & Clifton-Bligh, R. J. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.141 · Cited by 146
Cytotoxic Chemotherapy for Differentiated Thyroid Carcinoma
Sherman, S. I. (2010) · Clinical Oncology · doi:10.1016/j.clon.2010.03.014 · Cited by 142
Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy
Smith, N. R., Baker, D., Farren, M., Pommier, A., Swann, R., Wang, X., Mistry, S., McDaid, K., Kendrew, J., Womack, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1637 · Cited by 136
Fibroblast Growth Factor Receptors as Molecular Targets in Thyroid Carcinoma
St. Bernard, R., Zheng, L., Liu, W., Winer, D., Asa, S. L., & Ezzat, S. (2005) · Endocrinology · doi:10.1210/en.2004-1134 · Cited by 126
Vascular Endothelial Growth Factor: A Therapeutic Target for Tumors of the Ewing's Sarcoma Family
Dalal, S., Berry, A. M., Cullinane, C. J., Mangham, D. C., Grimer, R. J., Lewis, I. J., Johnston, C., Laurence, V., & Burchill, S. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1201 · Cited by 118
The role of the PAX8/PPARγ fusion oncogene in the pathogenesis of follicular thyroid cancer
Eberhardt, N. L., Grebe, S. K. G., McIver, B., & Reddi, H. V. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.10.013 · Cited by 114
Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease
Busaidy, N. L., & Cabanillas, M. E. (2012) · Journal of Thyroid Research · doi:10.1155/2012/618985 · Cited by 108
Panek, R. L., Lu, G. H., Dahring, T. K., Batley, B. L., Connolly, C., Hamby, J. M., & Brown, K. J. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37619-0 · Cited by 86
Genetic Alterations in Poorly Differentiated and Undifferentiated Thyroid Carcinomas
Soares, P., Lima, J., Preto, A., Castro, P., Vinagre, J., Celestino, R., P. Couto, J., Prazeres, H., Eloy, C., Maximo, V., et al. (2011) · Current Genomics · doi:10.2174/138920211798120853 · Cited by 85
Role of MEN2A-Derived RET in Maintenance and Proliferation of Medullary Thyroid Carcinoma
Drosten, M., Hilken, G., Bockmann, M. R., Rödicker, F., Mise, N., Cranston, A. N., Dahmen, U., Ponder, B. A. J., & Pützer, B. M. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh226 · Cited by 71
Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience
Lim, S. M., Shin, S. J., Chung, W. Y., Park, C. S., Nam, K., Kang, S., Keum, K. C., Kim, J. H., Choi, Y., Hong, Y. K., et al. (2012) · Yonsei Medical Journal · doi:10.3349/ymj.2012.53.2.352 · Cited by 70
Anderson, R. T., Linnehan, J. E., Tongbram, V., Keating, K. N., & Wirth, L. J. (2013) · Thyroid · doi:10.1089/thy.2012.0520 · Cited by 70
Erdem, H., Gündoğdu, C., & Şipal, S. (2011) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2011.01.008 · Cited by 61
Wong, K., & Lang, B. H. (2012) · Journal of Thyroid Research · doi:10.1155/2012/818204 · Cited by 21
Yagi, M., Kato, S., Kobayashi, Y., Kubo, K., Oyama, S., Shimizu, T., Nishitoba, T., Isoe, T., Nakamura, K., Ohashi, H., et al. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3616 · Cited by 16
New Insight into the Treatment of Advanced Differentiated Thyroid Cancer
Safavi, A., Vijayasekaran, A., & Guerrero, M. A. (2012) · Journal of Thyroid Research · doi:10.1155/2012/437569 · Cited by 13
Correction: Molecular genetics of multiple endocrine neoplasia types 1 and 2
Marx, S. J. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1690 · Cited by 3
Research works printed but not linked: 1
- 2002, Cancer Research, 62, 5749
Cited by
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors
Rimkus, T., Carpenter, R., Qasem, S., Chan, M., & Lo, H.-W. (2016) · Cancers · doi:10.3390/cancers8020022 · Cited by 581
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer
Makker, V., Taylor, M. H., Aghajanian, C., Oaknin, A., Mier, J., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., DiSimone, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02627 · Cited by 522
Metadata
- Authors
- Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y.
- Affiliations
- Eisai (Japan) (JP)
- Eisai (United States) (US)
- Corresponding author
- Funahashi, Yasuhiro
- ORCID
- Venue
- Journal of Thyroid Research
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-13
- ISSN
- 2042-0072 (ISSN-L)
- 2090-8067
- PMC
- PMC4177084
- OpenAlex
- W2094109552
- Cited by
- 475
- References
- 50
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 49 · 2023: 69 · 2022: 57 · 2021: 69 · 2020: 52 · 2019: 53 · 2018: 38 · 2017: 17 · 2016: 18 · 2015: 12 · 2014: 1
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Thyroid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- lenvatinib, thyroid cancer, angiogenesis inhibition, VEGF receptor signaling, FGFR1, RET, receptor tyrosine kinase inhibitors, anaplastic thyroid carcinoma, medullary thyroid carcinoma, differentiated thyroid cancer, xenograft models, antiproliferative activity, FRS2, KIT, PDGFRA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.